As per the terms of this collaboration, Kollmann is expected to use Advaxis proprietary Listeria vaccine vectors for the development of novel infectious disease applications, and employ a post-doctoral fellow who will be dedicated to the creation and assessment of novel infectious disease vaccines and new delivery forms of live attenuated Listeria vaccines.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer
Kollmann is an immunologist and neonatal vaccinologist who has published on the use of Listeria vaccines as potential therapeutic agents for the treatment of childhood diseases.